Effect of dolutegravir-based first-line antiretroviral therapy on weight and body mass index among adult people living with HIV on follow up at health facilities in Hawassa city administration, Southern Ethiopia: a retrospective cohort study

References

• Yuh B, Tate J, Butt AA, et al. Weight change after antiretroviral therapy and mortality. Clin Infect Dis. 2015;60(12):1–12. doi: 10.1093/cid/civ192.
   PubMed Web of Science ®Google Scholar
• Madec Y, Szumilin E, Genevier C, et al. Weight gain at 3 months of antiretroviral therapy is strongly associated with survival: evidence from two developing countries. AIDS. 2009;23(7):853–861. doi: 10.1097/QAD.0b013e32832913ee.
   PubMed Web of Science ®Google Scholar
• Kumar S, Samaras K. The impact of weight gain during HIV treatment on risk of pre-diabetes, diabetes mellitus, cardiovascular disease, and mortality. Front Endocrinol (Lausanne). 2018;9:705. doi: 10.3389/fendo.2018.00705.
   PubMed Web of Science ®Google Scholar
• Achhra A, Mocroft A, Reiss P, et al. Short-erm weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the study. HIV Med. 2016;17(4):255–268. doi: 10.1111/hiv.12294.
   PubMed Web of Science ®Google Scholar
• Herrin M, Tate JP, Akgün KM, et al. Weight gain and incident diabetes among HIV infected-veterans initiating antiretroviral therapy compared to uninfected individuals. J Acquir Immune Defic Syndr. 2016;73(2):228–236. doi: 10.1097/QAI.0000000000001071.
   PubMed Web of Science ®Google Scholar
• National Health Service (NHS). Obesity. 2019 [cited 2022 Sep 30]. Available from: https://www.nhs.uk/conditions/obesity/
   Google Scholar
• World Health Organization (WHO). Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidelines: supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. World Health Organization; 2018.
   Google Scholar
• Fantauzzi A, Mezzaroma I. Dolutegravir: clinical efficacy and role in HIV therapy. Ther Adv Chronic Dis. 2014;5(4):164–177. doi: 10.1177/2040622314530461.
   PubMedGoogle Scholar
• Bourgi K, Rebeiro PF, Turner M, et al. Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy. Clin Infect Dis. 2020;70(7):1267–1274. doi: 10.1093/cid/ciz407.
   PubMed Web of Science ®Google Scholar
• Sax PE, Erlandson KM, Lake JE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020;71(6):1379–1389. doi: 10.1093/cid/ciz999.
   PubMed Web of Science ®Google Scholar
• FMoH. Federal Ministry of Health of Ethiopia, National consolidated guidelines for comprehensive HIV prevention, care and treatment 2018 [cited 2021 Sep 30]. Available from: https://www.humanitarianresponse.info/sites/www.humanitarianresponse. info/files/documents/files/national_comprehensive_hiv_care_guideline_2018-endorsed.pdf.
   Google Scholar
• World Health Organization (WHO). Progress report 2016: prevent HIV, test and treat all: WHO support for country impact. World Health Organization; 2016.
   Google Scholar
• Federal Ministry of Health. National guidelines for comprehensive HIV prevention, care and treatment. Ethiopia: Federal Ministry of Health Addis Ababa; 2017.
   Google Scholar
• Van Leth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med. 2004;1(1):e19. doi: 10.1371/journal.pmed.0010019.
   PubMed Web of Science ®Google Scholar
• Taramasso L, Bonfanti P, Ricci E, et al. Factors associated with weight gain in people treated with dolutegravir. Open Forum Infect Dis. 2020;7(6):ofaa195. doi: 10.1093/ofid/ofaa195.
   PubMed Web of Science ®Google Scholar
• Pérez SE, Chow SP, Kania A, et al. Weighing in on the role of integrase strand transfer inhibitors (INSTIs) on weight gain: fact or fiction? Curr Infect Dis Rep. 2020;22(7):1–11. doi: 10.1007/s11908-020-00727-w.
   PubMed Web of Science ®Google Scholar
• Eckard AR, McComsey GA. Weight gain and integrase inhibitors. Curr Opin Infect Dis. 2020;33(1):10–19. doi: 10.1097/QCO.0000000000000616.
   PubMed Web of Science ®Google Scholar
• Weir CB, Jan A. BMI classification percentile and cut off points. 2019.
   Google Scholar
• Garrow JS, Webster J. Quetelet’s index (W/H2) as a measure of fatness. Int J Obes. 1985;9(2):147–153.
   PubMed Web of Science ®Google Scholar
• Venter WD, Moorhouse M, Sokhela S, et al. Dolutegravir plus two different prodrugs of Tenofovir to treat HIV. N Engl J Med. 2019;381(9):803–815. doi: 10.1056/NEJMoa1902824.
   PubMed Web of Science ®Google Scholar
• Group NAS. Dolutegravir-based or low-dose efavirenz–based regimen for the treatment of HIV-1. New Eng J Med. 2019;381(9):816–826.
   PubMed Web of Science ®Google Scholar
• Hill A, Waters L, Pozniak A. Are new antiretroviral treatments increasing the risks of clinical obesity? J Virus Erad. 2019;5(1):41–43. doi: 10.1016/S2055-6640(20)30277-6.
   PubMed Web of Science ®Google Scholar
• Huszar D, Lynch CA, Fairchild-Huntress V, et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell. 1997;88(1):131–141. doi: 10.1016/s0092-8674(00)81865-6.
   PubMed Web of Science ®Google Scholar
• Use CfMPfH. European medicines agency committee for medicinal products for human use (CHMP) guideline on the evaluation of anticancer medicinal products in man. London: European Medicines Agency; 2006.
   Google Scholar
• Burns JE, Stirrup OT, Dunn D, et al. No overall change in the rate of weight gain after switching to an integrase-inhibitor in virologically suppressed adults with HIV. AIDS. 2020;34(1):109–114. doi: 10.1097/QAD.0000000000002379.
   PubMed Web of Science ®Google Scholar
• Ciccullo A, Dusina A, Lassandro AP, et al. No significant changes in body fat mass in virologically suppressed, HIV-positive patients switched to lamivudine–dolutegravir. AIDS. 2020;34(6):956–957. doi: 10.1097/QAD.0000000000002495.
   PubMed Web of Science ®Google Scholar
• Norwood J, Turner M, Bofill C, et al. Weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens. J Acquir Immune Defic Syndr. 2017;76(5):527–531. doi: 10.1097/QAI.0000000000001525.
   PubMed Web of Science ®Google Scholar
• Zimmerman M, DeSimone J, Schafer JJ. 332. Exploring the prevalence and characteristics of weight gain and other metabolic changes in patients with HIV infection switching to integrase inhibitor containing ART. Open Forum Infect Dis. 2019;6(Supplement_2):S176–S177. doi: 10.1093/ofid/ofz360.405.
   Google Scholar
• Kerchberger AM, Sheth AN, Angert CD, et al. Weight gain associated with integrase stand transfer inhibitor use in women. Clin Infect Dis. 2020;71(3):593–600. doi: 10.1093/cid/ciz853.
   PubMed Web of Science ®Google Scholar
• Lake JE, Wu K, Bares SH, et al. Risk factors for weight gain following switch to integrase inhibitor–based antiretroviral therapy. Clin Infect Dis. 2020;71(9):e471–e7. doi: 10.1093/cid/ciaa177.
   PubMed Web of Science ®Google Scholar
• Bhagwat P, Ofotokun I, McComsey GA, et al. Changes in waist circumference in HIV-infected individuals initiating a raltegravir or protease inhibitor regimen: effects of sex and race. Open Forum Infect Dis. 2018;5(11):ofy201. doi: 10.1093/ofid/ofy201.
   PubMed Web of Science ®Google Scholar
• Baraki AG, Gezie LD, Zeleke EG, et al. Body mass index variation over time and associated factors among HIV-positive adults on second-line art in North-west Ethiopia: a retrospective follow-up study. BMJ Open. 2019;9(9):e033393. doi: 10.1136/bmjopen-2019-033393.
   PubMed Web of Science ®Google Scholar
• Weldesenbet AB, Ayele TA, Sisay MM, et al. Predictors of change in weight among people living with HIV on antiretroviral treatment in west hararghe zone, Ethiopia: a retrospective longitudinal study. HIV AIDS (Auckl). 2020;12:373–380.
   Google Scholar
• Alebel A, Demant D, Petrucka PM, et al. Weight change after antiretroviral therapy initiation among adults living with HIV in northwest Ethiopia: a longitudinal data analysis. BMJ Open. 2022;12(2):e055266. doi: 10.1136/bmjopen-2021-055266.
   PubMed Web of Science ®Google Scholar
• Pantazis N, Papastamopoulos V, Antoniadou A, et al. Changes in body mass index after initiation of antiretroviral treatment: differences by class of core drug. Viruses. 2022;14(8):1677. doi: 10.3390/v14081677.
   PubMed Web of Science ®Google Scholar
• Martínez-Sanz J, Blanco JR, Muriel A, et al. Weight changes after antiretroviral therapy initiation in CoRIS (Spain): a prospective multicentre cohort study. J Int AIDS Soc. 2021;24(5):e25732. doi: 10.1002/jia2.25732.
   PubMed Web of Science ®Google Scholar
• Bakal DR, Coelho LE, Luz PM, et al. Obesity following ART initiation is common and influenced by both traditional and HIV-/ART-specific risk factors. J Antimicrob Chemother. 2018;73(8):2177–2185. doi: 10.1093/jac/dky145.
   PubMed Web of Science ®Google Scholar
• Kim J, Nam H-J, Jung Y-J, et al. Weight gain and lipid profile changes in koreans with human immunodeficiency virus undergoing integrase strand transfer Inhibitor-Based regimens. Infect Chemother. 2022;54(3):419–432. doi: 10.3947/ic.2022.0063.
   PubMed Web of Science ®Google Scholar
• Bourgi K, Jenkins CA, Rebeiro PF, et al. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. J Int AIDS Soc. 2020;23(4):e25484. doi: 10.1002/jia2.25484.
   PubMed Web of Science ®Google Scholar
• Semu H, Zack RM, Liu E, et al. Prevalence and risk factors for overweight and obesity among HIV-infected adults in Dar Es Salaam, tanzania. J Int Assoc Provid AIDS Care. 2016;15(6):512–521. doi: 10.1177/2325957414542574.
   PubMedGoogle Scholar
• Clayden P. Weight gain and metabolic syndrome with dolutegravir and TAF: results from the ADVANCE trial. 17th European AIDS Conference (EACS 2019); 15 November 2019. EACS 17 Basel 2019. 2019.
   Google Scholar
• Bares SH, Smeaton LM, Xu A, et al. HIV-infected women gain more weight than HIV-infected men following the initiation of antiretroviral therapy. J Womens Health (Larchmt). 2018;27(9):1162–1169. doi: 10.1089/jwh.2017.6717.
   PubMed Web of Science ®Google Scholar
• Bansi-Matharu L, Phillips A, Oprea C, et al. Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium. Lancet HIV. 2021;8(11):e711–e22. doi: 10.1016/S2352-3018(21)00163-6.
   PubMed Web of Science ®Google Scholar